Researchers at the University of Pittsburgh School of Medicine have learned that some healthy people naturally developed an immune response against a protein that is made in excess levels in many cancers, including breast, lung, and head and neck cancers. The finding suggests that a vaccine against the protein might prevent malignancies in high-risk individuals.

After a vaccination or an infection, the human immune system remembers to keep protecting against invaders it has already encountered, with the aid of specialized B-cells and T-cells. Immunological memory has long been the subject of intense study, but the underlying cellular mechanisms regulating the generation and persistence of long-lived memory T cells remain largely undefined.

Researchers at the University of Pittsburgh School of Medicine have begun testing a vaccine that might be able to prevent colon cancer in people at high risk for developing the disease.

Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vaccine.

Scientists use the tobacco plant to “grow” key components of a cancer vaccine,and when I first saw this I was in a state of shock myself until I realized what they were actually doing.

Among patients with castration-resistant prostate cancer, the addition of hormone therapy following vaccine treatment improved overall survival compared with either treatment alone or when the vaccine followed hormone treatment, according to recent data published in the July 15 Clinical Cancer Research, a journal of the American Association for Cancer Research.

Immune Science Associates Assessment Analyzes Evolving Strategies

Taking advantage of the fact that the intestines have a separate immune system from the rest of the body, scientists at the Kimmel Cancer Center at Jefferson in Philadelphia have found a way to immunize mice against the development of metastatic disease.

Members and Friends of CareToLive took to the streets in 10 cities across America on May 30, 2008. Why? To continue to tell the story about how some folks at the FDA were busy serving themselves when they were supposed to be serving the people of this great nation. To continue to tell the story about how 30,000 men, today, are in desperate need of a treatment for their prostate cancer, and how the FDA wrongly denied them some help.

What if we could prevent cancer recurrence for years after surgery by giving simple recall injections every two or three years" This concept may no longer be a fantasy.

Researchers at the University of Southern California have developed a prostate cancer vaccine that prevented the development of cancer in 90 percent of young mice genetically predestined to develop the disease.